Despite the importance of chemotherapy-associated adverse events in oncology practice
and the broad range of interventions available to mitigate them, limited systematic efforts …

Purpose This review provides an update on the current clinical, epidemiological and
pathophysiological evidence alongside the diagnostic, prevention and treatment approach …

PURPOSE To update the ASCO guideline on the recommended prevention and treatment
approaches in the management of chemotherapy-induced peripheral neuropathy (CIPN) in …

Non‐invasive cancer photothermal therapy (PTT) is a promising replacement for traditional
cancer treatments. The second near‐infrared region induced PTT (NIR‐II PTT, 1000–1500 …

Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing
impact as oncological treatments, using potentially neurotoxic chemotherapy, improve …

Introduction Neo/adjuvant therapy for early-stage breast cancer has become increasingly
common in the last few decades; as a consequence, the number of breast cancer survivors …

Central and especially peripheral neurotoxicities due to systemic antineoplastic therapy are
common and often dose-limiting side-effects. In patients with chemotherapy (ChT)-induced …

TB affects around 10.6 million people each year and there are now around 155 million TB
survivors. TB and its treatments can lead to permanently impaired health and wellbeing. In …

PURPOSE Successful completion of chemotherapy is critical to improve breast cancer
outcomes. Relative dose intensity (RDI), defined as the ratio of chemotherapy delivered to …

Cancer diagnosis and treatment are drastic events for patients and their families. Besides
psychological aspects of the disease, patients are often affected by severe side effects …